Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
OA
OmniAb, Inc. Warrant
OABIW
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
OA
OABIW
OA
OmniAb, Inc. Warrant
OABIW
News
·
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
Mkt Cap
N/A
Volume
N/A
Next Earnings
N/A
Chart
Financials
Earnings
News
About
Insider
Filings
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 shows no year-over-year change at -$0.35 per share, but analysts have raised estimates by 10.3% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation.
Zacks Investment Research · Oct 6, 2026
AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
The article compares AbbVie and Eli Lilly as pharmaceutical investment options for 2026. AbbVie focuses on immunology and neuroscience with revenue of $61.2B and faces patent expiration risks, while Eli Lilly is experiencing explosive 45% revenue growth driven by its GLP-1 drugs (Mounjaro and Zepbound) with projected 2026 revenue of $85.2B. Despite Eli Lilly's higher valuation, the article recommends it for long-term investors due to the sustained demand and lifecycle nature of its metabolic therapies.
The Motley Fool · Aug 29, 2026
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The company is actively pursuing partnerships and reported strong industry interest in its novel BiTAC technology.
GlobeNewswire Inc. · Jul 6, 2026
AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway
AI is transforming healthcare through innovative technologies like disease screening, genetic testing, antibody discovery, and drug development platforms, with several companies making significant technological advancements in medical AI applications.
Benzinga · Jun 30, 2025
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
VERAXA Biotech and OmniAb have entered a co-discovery alliance to develop a novel bispecific antibody drug conjugate program targeting solid tumors. The partnership combines VERAXA's ADC technology with OmniAb's antibody discovery solutions.
GlobeNewswire Inc. · May 5, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
OA
OABIW
OmniAb, Inc. Warrant
Buy
Sell
Market
Limit
Soon
OABIW
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any OABIW yet.
Related Tickers
Earnings